Compare Incyte Corporation (INCY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Monster Beverage Corp — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Monster Beverage Corp trades at $46.06 (market cap $89.20B). The key difference: Monster Beverage Corp is far larger — about 3.6× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| INCY | MNST | |
|---|---|---|
Market Cap | $24.54B | $89.20B |
Sector | Health | Consumer Staples |
52-Week High | $129.93 | $49.97 |
52-Week Low | $81.61 | $30.86 |
Enterprise Value | $20.04B | $87.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Monster Beverage (MNST) trades at $45.895, up 0.45% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $8.29B and net income of $1.91B, achieving a 23.08% net margin. Recent Q2 2026 results beat expectations with $0.60 EPS versus $0.59 expected, driven by international growth. A 2-for-1 stock split occurred on August 11, 2026, while analyst consensus remains positive with 51% buy ratings and a $51.14 price target.
MNST's outlook is supported by robust earnings growth and global expansion, but elevated valuation ratios (P/E 42.16, P/S 9.75) pose risks. Competitive pressures in the energy drink sector and macroeconomic sensitivity could challenge margins. Institutional sentiment is cautiously optimistic, with upside potential to the consensus target representing 11% gain from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
